Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has…
Revenues Increased 12% to $28.3 Million, Including the Renewal of Two Delayed Contracts with the New York City Police Department…
Delivered Revenue and Adjusted EBITDA in the top end of Guidance Range First Quarter Revenue Growth Roughly Flat Year-Over-Year; Revenue…
Achieves Revenue In Line With Expectations With Record Gross MarginVIENNA, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Urgent.ly Inc. (Nasdaq:…
DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification…
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat…
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD)…
- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill®…
SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Energous Corporation d/b/a Energous Wireless Power Solutions (NASDAQ: WATT) (the “Company,”…
Revenue grew 37%, driven by increased product sales and service revenueREDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer,…
This website uses cookies.